May 7, 2021 -- WuXi Biologics has acquired manufacturing facilities from Bayer in Germany and from Pfizer in China. The company has also acquired CMAB Biopharma, a biologics contract development and manufacturing organization (CDMO) in China.
Under an agreement with Bayer, WuXi has taken over operations and assets of a drug substance facility located in Wuppertal, Germany, which includes three 1,000-L prefusion and six 2,000-L fed-batch bioreactors with independent downstream suites.
In March, WuXi acquired a biologics drug substance and product facility from Pfizer located in Hangzhou, China. This facility includes two 2,000-L single-use bioreactors that can be expanded to four bioreactors. The site also contains two drug product manufacturing facilities for drug product formulation and vial/syringe filling.
Lastly, WuXi acquired CMAB, which has operations in Suzhou, China. CMAB facilities include 7,000-L bioreactor drug substance capacity as well as drug product manufacturing for liquid and lyophilization fills. WuXi Biologics acquired 100% interest of CMAB, which will be renamed as WuXi Biologics (Suzhou) and operate as a wholly owned subsidiary.
With these acquisitions, WuXi Biologics has 11 facilities in China, the U.S., and Germany with a good manufacturing practice (GMP) manufacturing capacity of over 150,000-L. Moreover, the company will now have nine GMP drug product facilities for vials and syringes.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
